Viatris Clears US Symbicort Hurdle But Loses Key Patent Fight To AstraZeneca
Three US Patents Not Invalid Due To Obviousness; Appeal Planned
Viatris and partner Kindeva Drug Delivery are celebrating a first tentative nod for a generic to one of the most significant respiratory opportunities in the US, but cannot launch at present with the firms having failed to navigate key pieces of intellectual property.
